Levosimendan and gut mucosal blood flow - Not all inotropes are created equal

Critical Care Medicine

Volumn 33, Issue 1, 2005, Pages 246-247

  Coopersmith, Craig M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood flow; Dobutamine; Gut; Inotrope; Intestine; Levosimendan; Milrinone

Indexed keywords

DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE;

DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDICATION; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG USE; EDITORIAL; ENDOTOXEMIA; HEART FAILURE; HEART OUTPUT; HUMAN; HYPERTENSION; INOTROPISM; INTENSIVE CARE; INTESTINE BLOOD FLOW; INTESTINE MUCOSA; LOW DRUG DOSE; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; OXYGENATION; PRIORITY JOURNAL; SURVIVAL; VASODILATATION;

ANIMALS; CARDIOTONIC AGENTS; DOBUTAMINE; DOGS; GASTRIC MUCOSA; HEMOGLOBINOMETRY; HYDRAZONES; MICROCIRCULATION; MILRINONE; OXYGEN CONSUMPTION; PYRIDAZINES; VASODILATOR AGENTS;

EID: 12244280827     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000150757.06161.D0     Document Type: Editorial

References (11)

1. Chen LW, Egan L, Li ZW, et al: The two faces of IKK and NF-kappaB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003; 9:575-581
2. Deitch EA, Forsythe R, Anjaria D, et al: The role of lymph factors in lung injury, bone marrow suppression, and endothelial cell dysfunction in a primate model of trauma-hemorrhagic shock. Shock 2004; 22:221-228
3. Coopersmith CM, Stromberg PE, Dunne WM, et al: Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA 2002; 287:1716-1721
4. Hassoun HT, Kone BC, Mercer DW, et al: Post-injury multiple organ failure: The role of the gut. Shock 2001; 15:1-10
5. Frishman WH: Advances in positive inotropic therapy: Levosimendan. Crit Care Med 2003; 31:2408-2409
6. Levijoki J, Pollesello P, Kaivola J, et al: Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: Structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol 2000; 32:479-491
7. Follath F, Cleland JG, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO Study): A randomised double-blind trial. Ann Mem Med 2002; 360:196-202
8. Yokoshiki H, Katsube Y, Sunagawa M, et al: Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997; 333:249-259
9. Pagel PS, Hettrick DA, Warltier DC: Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996; 119:609-615
10. Oldner A, Konrad D, Weitzberg E, et al: Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 2001; 29:2185-2193
11. Schwarte LA, Picker O, Bornstein SR, et al: Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med 2005; 33:135-142